Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation

Overview of attention for article published in Frontiers in oncology, May 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 15 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 6,534 followers.

New research: Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation: We report on a case of metastatic urothelial bladder carcinoma (mUBC) treated with… https://t.co

24 May 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.